These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28849750)

  • 1. Deciphering structural stability and binding mechanisms of potential antagonists with smoothened protein.
    Sinha N; Chowdhury S; Sarkar RR
    J Biomol Struct Dyn; 2018 Aug; 36(11):2917-2937. PubMed ID: 28849750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
    Sinha N; Chowdhury S; Sarkar RR
    Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Modelling of Berberine Derivatives as Inhibitors of Human Smoothened Receptor and Hedgehog Signalling Pathway Using a Newly Developed Algorithm on Anti-Cancer Drugs.
    Kaboli PJ; Bazrafkan M; Ismail P; Ling KH
    Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):384-400. PubMed ID: 28969581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Best Matching Protein Conformations and Docking Programs for a Virtual Screening Campaign Against SMO Receptor.
    Amendola G; Di Maio D; La Pietra V; Cosconati S
    Mol Inform; 2016 Sep; 35(8-9):340-9. PubMed ID: 27546038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand-based 3D pharmacophore modeling, virtual screening, and molecular dynamic simulation of potential smoothened inhibitors.
    Mohebbi A
    J Mol Model; 2023 Apr; 29(5):143. PubMed ID: 37062794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
    Zhang H; Sun Z; Liu Z; Song C
    Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of vismodegib resistance in D473G and W535L mutants of SMO receptor and design of novel drug derivatives using molecular dynamics simulations.
    Liao S; Floyd C; Verratti N; Leung L; Wu C
    Life Sci; 2020 Mar; 244():117302. PubMed ID: 31953165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triazoles bind the C-terminal domain of SMO: Illustration by docking and molecular dynamics simulations the binding between SMO and triazoles.
    Liu M; Liang G; Zheng H; Zheng N; Ge H; Liu W
    Life Sci; 2019 Jan; 217():222-228. PubMed ID: 30543826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State of the art of Smo antagonists for cancer therapy: advances in the target receptor and new ligand structures.
    Espinosa-Bustos C; Mella J; Soto-Delgado J; Salas CO
    Future Med Chem; 2019 Mar; 11(6):617-638. PubMed ID: 30912670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular modeling study on the dynamical structural features of human smoothened receptor and binding mechanism of antagonist LY2940680 by metadynamics simulation and free energy calculation.
    Bai Q; Shen Y; Jin N; Liu H; Yao X
    Biochim Biophys Acta; 2014 Jul; 1840(7):2128-38. PubMed ID: 24637074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colocalization Strategy Unveils an Underside Binding Site in the Transmembrane Domain of Smoothened Receptor.
    Zhou F; Ding K; Zhou Y; Liu Y; Liu X; Zhao F; Wu Y; Zhang X; Tan Q; Xu F; Tan W; Xiao Y; Zhao S; Tao H
    J Med Chem; 2019 Nov; 62(21):9983-9989. PubMed ID: 31408335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modeling study on resistance of WT/D473H SMO to antagonists LDE-225 and LEQ-506.
    Tu J; Li JJ; Song LT; Zhai HL; Wang J; Zhang XY
    Pharmacol Res; 2018 Mar; 129():491-499. PubMed ID: 29175550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.
    Lu W; Zhang D; Ma H; Tian S; Zheng J; Wang Q; Luo L; Zhang X
    Eur J Med Chem; 2018 Jul; 155():34-48. PubMed ID: 29857275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of anthranilamide derivatives as potent SMO inhibitors.
    Ji D; Zhang W; Xu Y; Zhang JJ
    Bioorg Med Chem; 2020 Mar; 28(6):115354. PubMed ID: 32063403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.
    Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M
    FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
    Halder AK; Saha A; Saha KD; Jha T
    J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing New Kinase Inhibitor Derivatives as Therapeutics Against Common Complex Diseases: Structural Basis of Microtubule Affinity-Regulating Kinase 4 (MARK4) Inhibition.
    Naz F; Shahbaaz M; Bisetty K; Islam A; Ahmad F; Hassan MI
    OMICS; 2015 Nov; 19(11):700-11. PubMed ID: 26565604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
    Arodola OA; Soliman ME
    Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol Interaction Sites on the Transmembrane Domain of the Hedgehog Signal Transducer and Class F G Protein-Coupled Receptor Smoothened.
    Hedger G; Koldsø H; Chavent M; Siebold C; Rohatgi R; Sansom MSP
    Structure; 2019 Mar; 27(3):549-559.e2. PubMed ID: 30595453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
    Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
    Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.